Bob Terbrueggen has 20 years of experience in the development of genomic tests and technologies. He started out his career at Clinical Micro Sensors (CMS), where as Director of R&D he oversaw the development of the world’s first bio-electronic DNA detection platform, the e-Sensor. Bob then became Director of Research at Motorola Life Sciences following Motorola’s acquisition of CMS on 2000 for $300 million. He then left Motorola to start DxTerity, a molecular diagnostic and information company that is transforming the management of chronic autoimmune disease with from home RNA monitoring.
Clinical Dx Showcase: DxTerity
DxTerity is a molecular diagnostic and information company transforming the management of chronic autoimmune disease with from home RNA monitoring. Powered by its patented DxCollect® home collection kit and DxDirect® genomic testing platform, DxTerity delivers high precision gene expression monitoring to improve patient care.
From Home Precision Medicine for Autoimmune Disease
DxTerity is bringing the power of precision medicine to autoimmune disease with its Autoimmune Profiler (AIP) test, a multi-module assay that monitors RNA expression of key immune pathways using a self-collected blood sample shipped by US mail.